Oxford Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Oxford Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-4,436	Closed	-$1.46M	–	799
2014 Q1	$1.46M	Buy	+4,436	New	+$1.5M	0.04%	413
2013 Q4	–	Sell	-22,404	Closed	-$1.55M	–	809
2013 Q3	$1.55M	Buy	+22,404	New	+$1.11M	0.03%	522

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Oxford Asset Management's ICPT Position: Q2 2014 in Review

Oxford Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2014, closing a stake of 4,436 shares — an estimated $1.46M sold.

Oxford Asset Management first reported a position in ICPT in Q3 2013 and held it in 2 quarters. The position peaked at $1.55M in Q3 2013. 167 funds tracked by Wall St. Rank hold ICPT as of Q2 2014.

Oxford Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
Oxford Asset Management sold 4,436 Intercept Pharmaceuticals, Inc. shares in Q2 2014, an estimated $1.46M.
Oxford Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2013 and held it in 2 quarters.
Oxford Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $1.55M in Q3 2013.
167 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2014.

Based on Oxford Asset Management's 13F filing for Q2 2014, filed 16 Jul 2014.